10% Owner ADAR1 Capital Buys $1.8M of Tenax Stock After Phase 3 Miss
TENX sits 45% above its 52-week low of $1.31.
Summary
ADAR1 Capital Management, a 10% owner, bought $1.81 million of Tenax stock over three days following the Phase 3 LEVEL trial miss.
Key Events · Ownership and Investor Activity · TENX
-
10% Owner Buys $1.8M in Open Market
ADAR1 Capital Management, LLC and Daniel Schneeberger purchased 1,025,867 shares for $1,814,147.49 across three transactions from August 20–24, 2026, at prices ranging from $1.70 to $1.80.
-
Post-Transaction Holdings Rise to 4.85M Shares
Following the purchases, the reporting persons hold 4,853,818 shares indirectly through private investment funds managed by ADAR1 Capital Management.
-
Purchase Follows Phase 3 LEVEL Trial Miss
The buying comes two weeks after the Phase 3 LEVEL trial of TNX-103 missed its primary endpoint on August 10, 2026, though prespecified subgroup and biomarker analyses showed signals.
-
Significant Stake Increase
The $1.81 million purchase represents approximately 2.6% of Tenax's market capitalization, a substantial commitment from a financial investor.
Analysis · TENX · Life Sciences
ADAR1 Capital Management, a 10% owner, bought 1,025,867 shares for $1.81 million across three days at $1.70–$1.80 per share. The purchase comes two weeks after the Phase 3 LEVEL trial missed its primary endpoint, which sent the stock down sharply. A large holder adding to its position at these levels is a notable vote of confidence in the subgroup and biomarker data management highlighted after the miss. The transaction represents roughly 2.6% of the company's market cap, making it a significant capital commitment from a financial investor.
How filings like this one have moved
In the 30 days to Sep 9, 2026, 36.4% of the 1919 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TENX was trading at $1.90 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $69.2M. The 52-week trading range was $1.31 to $19.40. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.